Anavex Life Sciences (AVXL) Amortizatization of Intangibles (2010 - 2016)
Anavex Life Sciences recorded quarterly Amortizatization of Intangibles of $4655.0 in Q3 2016, up 58087.5% quarter-over-quarter from $8.0 in Q2 2016, and down 99.67% year-over-year from $1.4 million in Q4 2015.
Anavex Life Sciences' Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at $4655.0 for Q3 2016.
- In Q3 2016, Amortizatization of Intangibles fell 99.67% year-over-year to $4655.0; the TTM figure through Sep 2016 stood at $5830.0 (down 99.87% YoY), while the FY2016 annual figure was $5830.0, down 99.87% from the prior year.
- Amortizatization of Intangibles came in at $4655.0 for Q3 2016 at Anavex Life Sciences, up from $8.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $2.6 million in Q2 2015 to a low of $8.0 in Q2 2016.
- A 4-year average of $499949.1 and a median of $7120.0 in 2014 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles jumped 3269571.25% in 2015 and tumbled 100.0% in 2016, its largest moves.
- Anavex Life Sciences' Amortizatization of Intangibles stood at $15293.0 in 2012, then slumped by 53.44% to $7120.0 in 2014, then tumbled by 84.62% to $1095.0 in 2015, then jumped by 325.11% to $4655.0 in 2016.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $4655.0, $8.0, and $72.0 for Q3 2016, Q2 2016, and Q1 2016 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13,267.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2016 | 4,655.00 |
| Sep 30, 2016 | 4,655.00 |
| Jun 30, 2016 | 8.00 |
| Jun 30, 2016 | 8.00 |
| Mar 31, 2016 | 72.00 |
| Mar 31, 2016 | 72.00 |
| Dec 31, 2015 | 1,095.00 |
| Dec 31, 2015 | 1,095.00 |
| Sep 30, 2015 | 1.41 Mn |
| Sep 30, 2015 | 1.41 Mn |
| Jun 30, 2015 | 2.62 Mn |
| Jun 30, 2015 | 2.62 Mn |
| Mar 31, 2015 | 486,331.00 |
| Mar 31, 2015 | 486,331.00 |
| Dec 31, 2014 | 7,120.00 |
| Dec 31, 2014 | 7,120.00 |
| Sep 30, 2014 | 1.92 Mn |
| Sep 30, 2014 | 1.92 Mn |
| Jun 30, 2014 | 80.00 |
| Jun 30, 2014 | 80.00 |
| Mar 31, 2014 | 1,011.00 |
| Mar 31, 2014 | 1,011.00 |
| Jun 30, 2012 | 15,293.00 |
| Jun 30, 2012 | 15,293.00 |
| Mar 31, 2012 | 44,613.00 |
| Mar 31, 2012 | 44,613.00 |
| Dec 31, 2011 | 38,175.00 |
| Dec 31, 2011 | 38,175.00 |
| Sep 30, 2011 | 40,019.00 |
| Sep 30, 2011 | 40,019.00 |
| Jun 30, 2011 | 29,400.00 |
| Jun 30, 2011 | 29,400.00 |
| Sep 30, 2010 | 595,319.00 |
| Sep 30, 2010 | 595,319.00 |